Working… Menu

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00024076
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : August 3, 2020
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

Brief Summary:

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.

PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Condition or disease Intervention/treatment Phase
Lung Cancer Malignant Mesothelioma Metastatic Cancer Thymoma and Thymic Carcinoma Procedure: radiofrequency ablation Phase 2

Detailed Description:


  • Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies.
  • Determine the efficacy of this treatment, in terms of local control, in these patients.
  • Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients.

OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours.

Patients are followed at 1, 3, 6, and 12 months.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Radiofrequency Ablation of Pulmonary Malignancy
Study Start Date : May 2000
Actual Primary Completion Date : December 2006

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of a primary or secondary intrathoracic malignancy

    • Any cell type or origin
    • Involving the intrapulmonary, mediastinal, or pleural/chest wall
    • Inoperable primary or metastatic cancer to the lung
  • Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
  • Single or multiple lesions that are non-contiguous with vital structures or organs such as:
  • Trachea
  • Heart
  • Aorta
  • Great vessels
  • Esophagus
  • Less than 5 cm in largest dimension
  • Accessible via percutaneous transthoracic route
  • Hepatic:

    • Coagulation profile normal

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00024076

Layout table for location information
United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Layout table for investigator information
Study Chair: Robert D. Suh, MD Jonsson Comprehensive Cancer Center
Layout table for additonal information
Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT00024076    
Other Study ID Numbers: CDR0000068889
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: August 3, 2020
Last Verified: July 2012
Keywords provided by Jonsson Comprehensive Cancer Center:
recurrent non-small cell lung cancer
recurrent small cell lung cancer
recurrent malignant mesothelioma
recurrent thymoma and thymic carcinoma
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
pulmonary carcinoid tumor
lung metastases
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Thymus Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Neoplasms, Mesothelial
Neoplasms, Complex and Mixed
Lymphatic Diseases